Maso Capital Partners’s Estrella Immunopharma ESLA Stock Holding History

Maso Capital Partners’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$11.5K	Hold	10,000	–	–	0.02%	36
2025 Q2	$9.6K	Hold	10,000	–	–	0.02%	23
2025 Q1	$9.27K	Hold	10,000	–	–	0.01%	27
2024 Q4	$12K	Hold	10,000	–	–	0.02%	25
2024 Q3	$11.6K	Hold	10,000	–	–	0.01%	25
2024 Q2	$10.5K	Hold	10,000	–	–	0.01%	20
2024 Q1	$12K	Hold	10,000	–	–	0.01%	28
2023 Q4	$11K	Hold	10,000	–	–	0.01%	19
2023 Q3	$93K	Buy	+10,000	New	+$101K	0.05%	28

Other funds holding ESLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ASM

ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Maso Capital Partners's ESLA Position: Q3 2025 in Review

Maso Capital Partners held its Estrella Immunopharma (ESLA) position steady in Q3 2025 at 10,000 shares worth $11.5K. The position accounts for 0.02% of the portfolio, ranked #36.

Maso Capital Partners first reported a position in ESLA in Q3 2023 and has held it in 9 quarters since. The position peaked at $93K in Q3 2023. 13 funds tracked by Wall St. Rank hold ESLA as of Q3 2025.

Maso Capital Partners held 10,000 shares of Estrella Immunopharma worth $11.5K as of Q3 2025.
Maso Capital Partners left its Estrella Immunopharma share count unchanged in Q3 2025.
Estrella Immunopharma made up 0.02% of Maso Capital Partners's portfolio in Q3 2025, its #36 holding.
Maso Capital Partners first reported a position in Estrella Immunopharma in Q3 2023 and has held it in 9 quarters since.
Maso Capital Partners's Estrella Immunopharma position peaked at $93K in Q3 2023.
13 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q3 2025.

Based on Maso Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.